Second- and third-generation drug-eluting coronary stents: progress and safety

Area of Science:

• Cardiovascular Medicine
• Biomaterials Engineering
• Interventional Cardiology

Background:

• Drug-eluting stents (DES) dramatically reduced in-stent restenosis compared to bare-metal stents (BMS).
• Widespread DES use identified safety concerns, particularly late stent thrombosis.
• Advancements in anti-restenotic agents and stent platforms aim to improve DES safety and efficacy.

Purpose of the Study:

• To review the evolution of DES technology, focusing on second- and third-generation devices.
• To assess the clinical performance of newer DES compared to older generations and BMS.
• To highlight the need for long-term data on emerging stent technologies.

Main Methods:

• Review of randomized controlled trials and registries comparing different DES generations and BMS.
• Analysis of technological advancements in DES, including anti-restenotic agents, coatings, and stent platforms.
• Evaluation of preclinical and initial clinical data for third-generation DES.

Main Results:

• Second-generation DES (ZES, EES) demonstrated favorable outcomes in trials and registries versus BMS and first-generation DES.
• Third-generation DES utilizing biodegradable polymers, polymer-free, or biodegradable materials show encouraging early results.
• Long-term, large-scale trial data comparing third-generation DES to current approved devices is currently limited.

Conclusions:

• Second-generation DES represent a significant improvement in treating coronary artery disease.
• Emerging third-generation DES technologies hold potential but require further extensive clinical validation.
• Continued research and long-term follow-up are crucial for establishing the safety and efficacy of novel DES.